SEA-CD40 utilizes our novel sugar-engineered antibody (SEA) technology to produce a non-fucosylated antibody targeting CD40. It builds on our extensive experience targeting CD40, an immune-activating receptor capable of driving an antitumor response. Preclinical data show that SEA-CD40 may stimulate a patient's own immune system to fight their cancer. A non-ADC program developed by our scientists, SEA-CD40 represents an alternative approach to empowering antibodies that is complementary to our ADC technology.
SEA-CD40 is in a phase 1 trial in metastatic or unresectable solid tumors and hematologic malignancies.